Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model
出版年份 2012 全文链接
标题
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 7, Pages 1188-1199
出版商
American Society of Hematology
发表日期
2012-12-22
DOI
10.1182/blood-2012-03-415646
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Jak2 Inhibitor, G6, Alleviates Jak2-V617F–Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow
- (2015) Annet Kirabo et al. NEOPLASIA
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
- (2012) Oliver Weigert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
- (2011) A. Tefferi et al. BLOOD REVIEWS
- Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients
- (2011) Carlos Besses et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mouse models of myeloproliferative neoplasms: JAK of all grades
- (2011) J. Li et al. Disease Models & Mechanisms
- The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
- (2011) R. A. Van Etten et al. HAEMATOLOGICA
- Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden
- (2011) I. R. Zalcberg et al. HAEMATOLOGICA
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
- (2010) C. Marty et al. BLOOD
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
- (2010) H. Akada et al. BLOOD
- JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
- (2010) J. Li et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
- (2010) Edwin Chen et al. CANCER CELL
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
- (2010) E. Antonioli et al. HAEMATOLOGICA
- Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
- (2010) F. Baffert et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
- (2009) P. C.C. Liu et al. CLINICAL CANCER RESEARCH
- Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden
- (2009) Thomas Stauffer Larsen et al. Hematology
- Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients
- (2008) Emmanouil Spanoudakis et al. ANNALS OF HEMATOLOGY
- Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
- (2008) S. Xing et al. BLOOD
- JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
- (2008) I. Plo et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia
- (2008) A. Ricksten et al. HAEMATOLOGICA
- Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy
- (2008) F. Girodon et al. HAEMATOLOGICA
- The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders
- (2008) A. Theocharides et al. HAEMATOLOGICA
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now